Podcasts about Novartis

In this episode of the ‘AI in Business' podcast, Scott Bradley, VP of AI and Innovation at Novartis, returns to discuss how AI is reshaping decision-making at the earliest stages of drug development—and what that means for the future of pharma investment strategy. Host Matthew DeMello and Scott explore how the pharmaceutical industry is transitioning from intuition-led portfolio choices to data-driven precision. They discuss the growing influence of AI in identifying viable drug candidates, designing complex proteins, and even solving long-standing manufacturing challenges. Scott also highlights the impact of AI on shifting portfolio dynamics—enabling pharma companies to target smaller, more specific patient populations and scale up development across a wider range of therapies. With AI now central to everything from molecule discovery to commercialization, the conversation offers a window into how life sciences organizations must adapt both structurally and strategically to stay competitive. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! This episode is sponsored by Intelligencia AI. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

This episode covers: Cardiology This Week: A concise summary of recent studies The role of cardiac magnetic resonance in myocardial disease Air pollution and heart disease Statistics Made Easy: Quasi-experimental study designs Host: Rick Grobbee Guests: Carlos Aguiar, Steffen Petersen, Mark Miller Want to watch that episode? Go to: https://esc365.escardio.org/event/1806 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Mark Miller have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Steffen Petersen Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1806?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This featured podcast includes a discussion with 3 experts on managing patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) from a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. In observational studies of treatment patterns in older women with mBC, approximately half of the patients were undertreated, and only half received a CDK4/6 inhibitor (CDK4/6i)-based regimen in the first-line setting. Reasons for undertreatment include concerns about the patient's age, perceived frailty, and underlying health issues. Aging is a heterogeneous process; older patients must receive individualized treatment that is not based solely on their age but on a comprehensive assessment that objectively assesses their overall health and ability to tolerate treatment. This program is designed to help clinicians assess the fitness of older patients with HR+/HER2– mBC, review the efficacy and safety of CDK4/6i in this patient population, and individualize treatment decision-making appropriately. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Today's faculty are: Hope S. Rugo, MD Director, Women's Cancers Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Duarte, CA Professor Emeritus, UCSF Disclosures: Grant/Research Support: Ambrx; AstraZeneca; Daiichi Sankyo, Inc; F. Hoffmann-La Roche AG/Genentech, Inc; Gilead Sciences, Inc; Lilly; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Stemline Therapeutics. Consultant: Napo Therapeutics; Puma Biotechnology; Sanofi. Honoraria: Chugai; Mylan/Viatris. Neil M. Iyengar, MD Associate Attending, Breast Medicine Service Program Lead, MSK Healthy Living Department of Medicine Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Adviser: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics. Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health. Editorial Position: npj Breast Cancer, Oncology®. Equity/Ownership: Complement Theory, Bettering Company. Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat's Ribbon of Hope, National Cancer Institute/National Institutes of Health. Contracted Research: Novartis, SynDevRx. Komal Jhaveri, MD, FACP Patricia and James Cayne Chair for Junior Faculty Associate Attending Physician, Breast Medicine Service and Early Drug Development Service Section Head, Endocrine Therapy Research Program Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center Associate Professor of Clinical Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc. Research Funding: AstraZeneca Pharmaceuticals LP, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Den andra delen av poddserien MS, kroppen och livet handlar om MS och immunsystemet. Gästar gör Lotta Dahle, neurolog och immunolog, som besitter en unik kunskap inom ämnet. Hon kommer att dela med sig av sina kunskaper och erfarenheter, och även svara på lyssnarfrågor.   Producerad på uppdrag av Novartis.

Dr. Arvīds Irmejs šajā sarunā atklāj dzīvību glābjošus faktus par vēzi. Dakteris parāda, kā vēzis attīstās un kā tas kļūst arvien viltīgāks laika gaitā, tāpēc agrīnai diagnostikai un mamogrāfijas metodei ir izšķiroša nozīme, lai glābtu dzīvību un saglabātu dzīves kvalitāti. Pat neliela kavēšanās var dramatiski mazināt izveseļošanās iespējas. Dakteris arī norāda, kā 40% vēža gadījumu ir novēršami ar dzīvesveida izmaiņām.Dr. Arvīds Irmejs ir krūts ķirurģijas virsārsts PSKUS. Viņš ir RSU asociētais profesors, Onkoloģijas un molekulārās ģenētikas institūta direktors. Latvijas ārstu biedrības ceremonijā "Gada balva medicīnā" viņš saņēma balvu "Gada cilvēks medicīnā 2021".Šajā sarunā ārsts stāsta par mūsdienu ārstēšanas iespējām, pateicoties kam 80% sieviešu ar krūts vēzi vairs nav jāuztraucas par krūts zaudēšanu. Dakteris sniedz gan praktisku informāciju par skrīninga iespējām Latvijā, gan emocionālu atbalstu un cerību. Tā ir saruna, kas daudzas sievietes un viņu ģimenes var pasargāt no priekšlaicīgas nāves novēloti konstatēta vēža dēļ.Šīs intervijas saturs ir veidots sociālās kampaņas ietvaros, kas veltīta krūts veselībai. Kampaņa Latvijā tiek organizēta sadarbojoties ar krūts vēža pacientēm, pacientu organizācijām, vēža pacientu atbalsta organizāciju Onkoalianse, vadošajiem ārstiem ķīmijterapeitiem un farmācijas uzņēmumu Novartis.Sarunā pieminētos informācijas avotus un saites atradīsi 228. sarunas lapā.SARUNAS PIETURPUNKTI:00:00 - Agrīnā diagnostika glābj dzīvības00:02 – Iepazīšanās ar Dr. Arvīdu Irmeju00:04 - Krūts slimību centra darbība un komanda00:05 - Darba ikdiena un izmaiņas ārsta karjerā00:06 - Vīriešu krūts vēzis - retāk sastopams, bet tas pastāv00:08 - Ticības loma ārsta darbā, kas Dr. Irmejam dod spēku 00:10 - Pozitīva komunikācija ar pacientiem, kad svarīgi fokusēties uz risinājumiem, nevis sliktākajiem scenārijiem.00:14 - Svarīgi, lai pacients nebūtu viens, saņemot diagnozi.00:19 - Mūsdienu iespējas saglabāt krūti00:22 - Māņticības ietekme uz vēža ārstēšanu00:26 - Komplementārās medicīnas loma - fizisko aktivitāšu, uztura un garīgās veselības nozīme vēža ārstēšanas procesā.00:28 - Dzīvesveida ietekme uz vēža attīstību00:30 - Reproduktīvie faktori un krūts vēža risks00:32 - Garīgās veselības ietekme uz imunitāti un vēža attīstību.00:36 - Traģiskās kavēšanās sekas, kuras var mazināt00:40 - Vēža attīstības process un agrīnas diagnostikas nozīme00:44 - Krūts vēža statistika un jaunāku sieviešu risks, kas jāņem vērā00:45 - Mamogrāfijas pieejamība, valsts apmaksātais skrīnings sievietēm no 50 gadu vecuma un ieteikumi jaunākām sievietēm00:47 - Mamogrāfijas metodes drošības skaidrojums00:48 - Krūts vēža statistika Latvijā00:49 - Agrīna diagnostika var samazināt mirstību par trešdaļu00:51 – Skaidrojums, kādas ir mamogrāfijas priekšrocības pār citām metodēm00:54 - Godīga saruna par mamogrāfijas diskomfortu, kad ieguvumi no šī skrīninga atsver īslaicīgo diskomfortu.01:01 - Kā vīriešiem atbalstīt sievas, māsas, draudzenes krūts veselības pārbaudēs un ārstēšanas procesā01:03 - Pārmantotā vēža risks un ģenētiskās pārbaudes sievietēm01:06 – Interesanti pētījumi par krūšu palielināšanu un vēža risku01:07 - Nākotnes prognozes krūts vēža ārstēšanā, kad prevencija un veselīgs dzīvesveids ir efektīvākie risinājumi01:11 - Kā Dr. Irmejs saglabā līdzsvaru un atjaunojas01:14: Tava svarīgākā fotosesija

Grab your earphones! Get ready to listen and learn!

This Oncology PER®Spectives™ podcast explores the role of EZH2 in metastatic castration-resistant prostate cancer (mCRPC) progression and its synergy with androgen receptor inhibitors. In this podcast, experts Neeraj Agarwal, MD, FASCO; Himisha Beltran, MD; and Maha Hussain, MD, FACP, FASCO, discuss the management of mCRPC. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Accreditation/Credit Designation Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours. Instructions on How to Receive Credit Listen to this podcast in its entirety. Go to gotoper.com/credit and enter code: 6947 Answer the evaluation questions. Request credit using the drop-down menu. You may immediately download your certificate. Today's faculty are: Neeraj Agarwal, MD, FASCO Professor of Medicine Senior Director for Clinical Research HCI Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics Director, Genitourinary Oncology Program Huntsman Cancer Institute, University of Utah (NCI-CCC) Salt Lake City, UT Disclosures: Grant/Research Support (paid to institution): Arvinas, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Lava, Merck, Nektar, Neoleukin, Novartis, Oric, Pfizer, Roche, Sanofi, Seagen, Takeda, Tra-con Himisha Beltran, MD Associate Professor of Medicine Director of Translational Research Within Medical Oncology Harvard Medical School Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology Dana Farber Cancer Institute Boston, MA Disclosures: Grant/Research Support: Circle Pharma, Daiichi Sankyo, Novartis; Adviser: Amgen, AstraZeneca, Daiichi Sankyo, Novartis Maha Hussain, MD, FACP, FASCO Genevieve E. Teuton Professor of Medicine Professor, Medicine (Hematology/Oncology) Deputy Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, IL Disclosures: Advisory Board: AstraZeneca, Bayer, Convergent Therapeutics, Honoraria: AstraZeneca, Bayer The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity. Release Date May 14, 2025 Expiration Date May 14, 2026

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The White House has announced a new drug pricing policy that includes the revival of the most favored nations rule and extends to the private markets, leveraging the patent system, drug importation, and more. Meanwhile, Lilly's Zepbound has been found to have a superior benefit-risk ratio compared to Novo's Wegovy, BMS and Sanofi settle a Plavix lawsuit with Hawaii for $700 million, and biopharma companies are focusing on developing a cure for HIV as federal funding for related research is being cut. Sino Biological offers comprehensive solutions for autoimmune diseases, and Roche promises a $300 million investment in China production after a multibillion-dollar investment in the US. On the other hand, Lexeo and IGM have both announced significant layoffs. Novartis CEO has expressed concerns about Trump's pricing controls.Funding for HIV-related research and infrastructure is being cut by the Trump administration, leading biopharma companies like Gilead and Immunocore to focus on finding a cure for HIV. In the field of neurology, there is a need for more precise diagnostic tools to effectively treat neurodegenerative conditions. The new HHS vaccine requirement has been criticized by leading vaccine physician Paul Offit as potentially being anti-vaccine activism disguised as policy. Companies like Novartis, Bayer, and AstraZeneca are exploring new indications and innovations in radiopharmaceuticals, hoping to capitalize on a market that could reach $16 billion by 2033. The FDA has faced delays in reviewing certain drugs, while biotech stocks have fallen after the appointment of Vinay Prasad to succeed Marks at CBER. Vertex has decided to abandon AAV in the gene therapy space.Upcoming events include a webinar on surviving and thriving in the biotech downturn. Job opportunities in the biopharma industry include positions at Takeda, Daiichi Sankyo, and AbbVie. Heather McKenzie, senior editor at BioSpace, is open to suggestions for future coverage topics in neuroscience, oncology, cell & gene therapy, metabolic, or other areas.

Adam Friedman, MD, FAAD interviewed by Sabrina Shearer, MD, FAAD

While carrying the “ethos” of a Marketing Technologist to many enterprises, He's always possessed a firm understanding of how technology has continued to transform the discipline of Marketing while disrupting today's conventional consumer engagement models. Over that past 20+ years his communications experience ranges from African American, Hispanic, LGBT, Asian American, Arab American, Indian, Boomers, Millennials, Urban, GM to International.He's been an audience "segmentation specialist" for clients looking to enhance their brand positioning by rethinking and redefining their Go-To-Market approach. Some of them include the likes of Lexus, NYPD, Medline, State Fair, Spalding, HBO, MCD, LA Sparks, Game Show Network, Verizon Wireless, Clear brand under Unilever, Ford Division, Lincoln Mercury, Burger King, Colgate, HSBC, Time Warner Cable, Home Depot, AstraZeneca, US Marines, Pfizer, Novartis, Merck, and Hyatt Resorts.His vantage point is oriented around enhancing a clients' Brand building efforts through ROI driven programs that leverage unique consumer insights and deliver relevant customer experience. I've always thought outside the traditional framework to solving business problems because the only thing constant is EVOLUTION. He has also done guest speaking for Meltwater Social, MediaPost, Digiday, ThinkLA, CYNOPSIS, Adweek, and The VAB inclusive of live and virtual events.  In the past, he's participated in guest speaker series for NYU, Baruch, University of Maryland, University of Nevada, and Georgetown.  Tune into the  HYPERLINK "https://protect-us.mimecast.com/s/IvUyCwp2q2H2LpTVv9A2?domain=open.spotify.com" The Transient Identiti, podcast which chronicles the Voice of the Consumer.Other than Strategic Intuition and the Human Truths in Marketing, "gratitude" is one thing he value deeply in business. Meaning, being grateful for how open-minded he's been to constantly challenge and even disrupt my own thinking!

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

Donald Trump erwägt, auch auf Medikamente Zölle zu erheben. Dies würde die Schweiz hart treffen, die Pharmabranche ist ein bedeutender Sektor der Wirtschaft. Wie will der Branchenverband Interpharma die USA davon abhalten? Der Chef von Interpharma ist zu Gast im Tagesgespräch. Die USA sind ein wichtiger Absatzmarkt für Schweizer Pharma-Firmen. Präsident Trump sieht die Versorgungssicherheit der USA in Gefahr, weil viele Medikamente importiert werden. Er droht darum, auch auf Medikamente Zölle zu erheben, damit die Produktion im Inland angekurbelt wird. Was würde das für die Schweiz bedeuten? Wie wollen sich die Schweizer Pharma-Firmen dagegen wehren? Und was heisst es für die Schweiz, wenn Novartis und Roche ihre Investitionen in die USA weiter ausbauen? Der Geschäftsführer von Interpharma, René Buholzer, spricht zum ersten Mal über die Position von Interpharma in dieser Frage, er ist zu Gast im Tagesgespräch.

This episode covers: Cardiology This Week: A concise summary of recent studies Colchicine for secondary prevention An algorithmic approach to the workup of syncope Milestones: CIBIS II Host: Rick Grobbee Guests: Carlos Aguiar, Sanjit Jolly, Michele Brignole Want to watch that episode? Go to: https://esc365.escardio.org/event/1805 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Sanjit Jolly has declared to have potential conflicts of interest to report: grant support from Boston Scientific, honorarium from Boston Scientific, Shockwave, Abiomed, SIS, and Teleflex.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Michele Brignole Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1805?r  Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo Nordisk predicts a brighter future for Wegovy with the end of the semaglutide shortage, but analysts remain skeptical as Eli Lilly's Zepbound gains ground in sales. The new HHS vaccine requirement has raised questions about its true intentions, with leading vaccine physician Paul Offit criticizing the lack of clarity. Meanwhile, pharmaceutical imports from Ireland are on the rise, biotech stocks fell after Vinay Prasad was named to succeed Marks at CBER, and Lotte Biologics' ADC facility in Syracuse offers end-to-end services for antibody manufacturing. CRISPR's Casgevy is gaining traction with more gene therapy proof of concept expected in 2025, impacting M&A and IPOs in the biotech industry. Summit Pharmaceuticals is nearing the first global phase III data for Keytruda, set to lose exclusivity in 2028 and potentially face competition from biosimilars. A report suggests that low-price drug nations are benefiting from US innovation, undervaluing innovative medicines by 90%. VC financing in biopharma declined by 20% in Q1, but megarounds kept the median deal size high. M&A and IPOs faced challenges due to policy issues, leading to an increase in licensing deals. Novo vows to improve market access for Wegovy, while Trump orders FDA to ease US plant expansion and increase inspections of foreign facilities. BMS pledges a $40 billion investment in the US, Novartis makes M&A moves, and Lilly remains unfazed by CVS's decision to side with Novo in the obesity market battle. Some drugmakers are stockpiling products in the US amid Trump's trade war. NGM terminates half of its staff as its lead asset moves through a registrational study. Job opportunities in clinical quality assurance audit, RBQM central statistical monitoring, and field medical capabilities are available.

In this episode, Liz Cumby is joined by Liana Mari-Gordon, an expert in mechanical engineering and surgical training, to discuss best practices throughout the clinical trial phase of medical devices. Liana shares her experiences of learning how what "looks good on paper" may need to be updated when the device is in the hands of a physician. They delve into the importance of standardizing training, capturing and sharing field data, and maintaining honest conversations about challenges and successes. The episode also highlights methods to implement continuous improvements and ensure best practices are disseminated across users.In 2025, we're embarking on a MedDevice Training Journey: From clinical trials to standard of care. Join us all year long as we explore training at each stage of the product life cycle.Need help developing your clinical trial training strategies? Contact us at training@cumbyconsulting.com.Related Resources:Liana Mari-Gordon is the owner of Liana Mari Gordon Consulting LLC, providing project management, training operations, and device development services to help set teams up for successful execution of training programs. She has spent her career in the medical device and pharmaceutical industries ranging from small startups to Fortune 500 companies. As a mechanical engineer designing spinal implants and surgical instruments at Globus Medical, her experience conducting hands-on training, supporting surgical cases, and evaluating product complaints from the field formed her passion for informed use of product and positive user experience. She joined Orbit Biomedical, an ophthalmic medical device startup, and became a surgical technical expert responsible for clinical trial device and procedure training. Liana's responsibilities expanded to managing the logistics and execution of training programs and surgery support for a global team and multiple clinical trials as the startup merged with Gyroscope Therapeutics. As training operations lead, Liana led communication between cross functional teams to ensure readiness of and consistency across internal team members and trial sites. When acquired by Novartis, Liana was a key member in integrating existing practices within the larger organization and facilitating process improvements when needed. Liana earned a BS and MEng in mechanical engineering from Cornell University.Subscribe to our newsletter to hear more about the journey from clinical trials to standard of care! Click here to subscribe!Connect with us on LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Liana Mari-Gordon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cumby Consulting⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rachel Medeiros⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Liz Cumby⁠⁠⁠⁠⁠About Cumby Consulting: Cumby Consulting's team of professionals deliver innovative MedTech training services for physicians, sales representatives, teaching faculty, key opinion leaders and clinical development teams. Whether you need a complete training system developed to deliver revenue sooner or a discrete training program for a specific meeting, Cumby Consulting will deliver highly strategic, efficient programs with uncompromising standards of quality.

Enterprise Knowledge CEO Zach Wahl again speaks with Barry Byrne, Global Head of Knowledge Management at Novartis and founder and organizer of the Knowledge Summit Dublin conference.In this conversation, Zach and Barry discuss Barry's growing knowledge management team at Novartis, how to measure KM success, and best practices for conducting (and scaling!) knowledge capture before valuable team members leave an organization. They also share what they're most excited about at Knowledge Summit Dublin this year, especially the "salmon of knowledge." For more information on Knowledge Summit Dublin, check it out at ⁠https://www.knowledgesummitdublin.com/⁠.Click ⁠here⁠ to listen to Barry's first Knowledge Cast episode.To learn more about Enterprise Knowledge, visit us at: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠enterprise-knowledge.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.EK's Knowledge Base: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://enterprise-knowledge.com/knowledge-base/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Contact Us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://enterprise-knowledge.com/contact-us/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/enterprise-knowledge-llc/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter/X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/ekconsulting⁠⁠⁠

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novartis recently acquired Regulus for $1.7 billion, signaling a trend of increased M&A activity in the pharmaceutical industry. Many companies have hinted at upcoming deals during recent earnings calls, which is seen as a positive sign for the biopharma ecosystem amidst challenges like tariffs and potential drug pricing pressures. GSK remains optimistic about M&A opportunities despite the threat of tariffs, with CEO Emma Walmsley emphasizing a cautious and disciplined approach to dealmaking. Trilink Biotechnologies has introduced custom sets of mRNA for screening studies, offering flexibility and scalability for research needs. The AACR 2025 conference featured promising data from Marengo and Briacell, while Pfizer CEO Albert Bourla has been lobbying against pharmaceutical industry tariffs proposed by President Trump. Overall, the industry is seeing a mix of challenges and opportunities, with companies navigating trade tensions and economic uncertainties while also pursuing strategic growth through acquisitions and innovative research initiatives.Pharmaceutical companies are navigating political uncertainties, particularly in relation to tariffs and dealmaking with China. Major companies are investing billions in US manufacturing to avoid tariffs threatened by President Trump. Despite lobbying efforts, Trump has expressed national security concerns regarding the pharmaceutical industry. CEO-to-employee pay gaps in the industry remain significant. Novartis, GSK, and AstraZeneca are facing challenges and making strategic shifts in response to political and market conditions. Tariff uncertainty is impacting Q1 earnings, with companies like Merck taking significant financial hits. Despite these challenges, the industry remains active with mergers and acquisitions. Upcoming events and job opportunities in the biopharma sector are highlighted.

Die Schweiz ist zurück in Deutschland - an der Börse! Schweizer Aktien können endlich wieder problemlos gehandelt werden.

Die Ankündigungen von Roche und Novartis, Milliarden in den USA zu investieren, sorgten jüngst für Aufsehen und lösten hierzulande Sorgen über eine Standortschwächung aus. Sind die Summen womöglich als Abwendung von Europa zu verstehen? Weitere Themen: In der Schweiz erfreut sich das Homeoffice auch nach den Pademiejahren noch grosser Beliebtheit. Das zeigt der Blick auf Stellenportale im Internet: Die Zahl der Stellen, die zumindest teilweise Arbeit im Homeoffice anbieten, nimmt weiter zu. Im April 1955 wurde in den USA die Impfung gegen Kinderlähmung zugelassen. Seither hat die Krankheit zwar ihren Schrecken verloren, aber es gibt sie noch. Jüngst gab es in New York einen Erkrankungsfall und in Afghanistan und Pakistan ist Polio endemisch. Droht auch hierzulande eine Rückkehr der Krankheit?

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. AstraZeneca has decided to abandon its neuroscience research and focus on weight loss and immunology, following recent discontinuations in Alzheimer's and migraine research. FDA experts are urging Commissioner Makary to resist politicization of the agency. Novartis CEO dismisses tariffs but warns against Trump's pricing controls. Pfizer announces $1.7 billion in cost savings, including a revamp of its R&D organization. Trilink Biotechnologies introduces custom sets of mRNA for screening studies. Other news includes Steminent showcasing therapy for spinocerebellar ataxia, Regeneron's shares tumbling, and ABEONA receiving FDA approval for a gene therapy for a rare skin disease. In summary, AstraZeneca shifts focus, FDA concerns arise, Novartis CEO speaks out, Pfizer announces cost savings, Trilink Biotechnologies introduces new product, Steminent showcases therapy, Regeneron's shares tumble, and ABEONA receives FDA approval.

With new bladder cancer therapies on the horizon, Dr. Lalani and Dr. Wallis review promising trial results - including EVER, CREST and the CISTO Study -presented at this year's annual meeting. They also address key practical challenges for bladder cancer treatment, from both a medical oncologist and a urologic oncologist's perspective.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, J&J, Merck, Pfizer, Eisai and AbbVie.

Policy issues—particularly tariffs—loom large as Q1 2025 earnings season rolls on, with Pfizer , Novartis, AstraZeneca and many more all reporting this week. On Pfizer's call, CEO Albert Bourla called the Trump administration's national security concerns “legitimate,” but objected to the proposed tariffs in general. Meanwhile, Novartis CEO Vas Narasimhan brushed off the tariff risk but expressed concern over President Donald Trump's desire to bring back the ‘Most Favored Nations' rule.  Meanwhile, cancer conference season is in full swing, with the American Association for Cancer Research's annual event continuing in Chicago. Merck, GSK, Boehringer Ingelheim, Roche and others have presented highly anticipated data from some of their cornerstone cancer drugs and other candidates.  Turning to the latest news out of the FDA, newly minted Commissioner Marty Makary gave his first two big press interviews last week, making statements that both jibed with and contradicted recent reporting. And in the midst of the ongoing Novavax vaccine saga, many have raised concerns that the FDA could become politicized under the watch of HHS Secretary RFK Jr.  Finally, check out this week's BioPharm Executive stories, including a deep dive into the trend toward mining innovative therapies from China and BioSpace's annual report on pharma CEO-to-employee pay ratios. 

Despite the rally we've seen in the past few days, Deutsche Bank cuts its S&P 500 and S&P earnings target due to concerns about tariffs. We speak to the firms Chief U.S. equity strategist. Plus, Amazon gets caught in the political crosshairs ahead of earnings later this week. We breakdown the drama and how to position. And, Novartis reports a strong beat and says it can manage any tariffs that come ahead. We speak with the CEO. 

US President Trump is expected to soften the impact of his automotive tariffs, according to WSJ citing sources.Canada's ruling Liberals, led by Mark Carney, won the national election but will need to form a minority government.APAC stocks were mostly in the green but with gains capped following the choppy performance stateside.European equity futures indicate a slightly positive open with Euro Stoxx 50 future up 0.1% after the cash market finished with gains of 0.3% on Monday.DXY is attempting to claw back some of yesterday's losses, EUR/USD has slipped back onto a 1.13 handle, USD/JPY bounced from support at 142.Looking ahead, highlights include German GfK Consumer Sentiment, Spanish GDP, HICP, EZ Business Sentiment, US Advance Goods Trade, JOLTS Job Openings, ECB's Cipollone, BoE's Ramsden, SNB's Martin & US Treasury Secretary Bessent, Supply from UK & Italy.Earnings from Starbucks, Visa, Snap, PPG, SoFi, PayPal, JetBlue, Coca-Cola, UPS, Pfizer, Royal Caribbean, Spotify, HSBC, BP, AstraZeneca, Ocado, Entain Lufthansa, Porsche AG, Deutsche Bank, Capgemini, Amundi, Rexel, Scor, URW, Carlsberg, Novartis, Logitech & BBVA.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Milliardeneinbussen drohen: Drei Blockbuster-Medikamente von Novartis verlieren bald den Patentschutz. Trotzdem hebt der Konzern die Ziele an. Warum? Stefan Schneider, Pharma-Analyst bei Vontobel, sieht starke neue Produkte als entscheidende Hoffnungsträger. SMI: +0.35

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Pech für Intel, eine Übernahme bei Merck und die Jagd auf High Beta. Außerdem geht es um BYD, Pfizer, Merck, SpringWorks Therapeutics, Nestlé, Roche, Novartis, Richemont, Zürich, Straumann, Geberit, CI Com SA, BB Biotech, Cosmo Pharmaceuticals, LEM Holding, Cicor Technologies, Medmix, BioVersys, Stadler Rail AG, Bystronic, Allreal Holding und Cembra Money Bank, Bitcoin, Meyer Burger, Kudelski, Molecular Partners, BB Biotech, LEM Holding, COSMO Pharmaceuticals und Rieter Holding. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Host: Emer Joyce Guests: Joost Lumens and Nico Bruining Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1804?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.  Declarations of interests: Stephan Achenbach, Nico Bruining, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Joost Lumens has declared to have potential conflicts of interest to report: research grants from Medtronic (all grants paid to institute, Maastricht University). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Thibaut Victor-Michel, President of Novartis France, joins The Leadership Consultation as the first guest from the pharmaceutical industry. In this episode, Thibaut shares his career journey, which began in consulting before transitioning to Novartis in 2006. Over the years, he has held roles in strategy, sales, marketing, and general management, working across France, Switzerland, and the Netherlands.Thibaut emphasizes the importance of intentional career decisions, focusing on roles that offer opportunities for impact and learning. While his career path was deliberately designed to build the skills necessary for general management, he views geographic moves as more opportunistic and credits open discussions with his family for enabling flexibility. He shares insights on managing organizations of different sizes, explaining how smaller teams require resource optimization, while larger ones demand a focus on simplicity and alignment.Reflecting on innovation in the pharmaceutical industry, Thibaut highlights the critical need for early data generation to ensure market access and adoption. He discusses the challenges of driving behavioral change in healthcare, stressing the importance of understanding social, convenience, and economic factors that influence how new therapies are embraced by patients and professionals.Thibaut also speaks about leading major transformations, including the integration of two large divisions at Novartis France. He describes the need to balance rational decision-making with empathy, ensuring clarity of purpose while supporting his team through significant organizational change. His leadership philosophy focuses on balancing complementary principles, such as courage with respect, empowerment with accountability, and transparency with kindness, which helps him adapt to challenges while staying true to his values.On balancing work and personal life, Thibaut stresses the importance of recovery periods within professional life to sustain energy and focus. He also highlights the value of focusing on one area of personal growth at a time to drive meaningful progress.Please do not hesitate to share your feedback with us on our LinkedIn or Instagram pages and to give us a rating on Apple Podcast. This is very important to help us grow The Leadership Consultation community...   

This episode covers: Cardiology This Week: A concise summary of recent studies Hypertension in the elderly The digital twin in cardiology Snapshots Host: Emer Joyce Guests: Carlos Aguiar, Gianfranco Parati, Nico Bruining, Joost Lumens Want to watch that episode? Go to: https://esc365.escardio.org/event/1804 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Nico Bruining, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Joost Lumens has declared to have potential conflicts of interest to report: research grants from Medtronic (all grants paid to institute, Maastricht University). Gianfranco Parati has declared to have potential conflicts of interest to report: honoraria for lectures by Omron, Merck, Viatris, Somnomedics. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

As CEO of Porter Novelli, Jillian Janaczek manages talent and operations of the strategic communications company globally, nurturing key client relationships, and driving business growth across Health, Corporate + Brand, Food + Ag + Nutrition, Purpose + Impact, Tech, and Government, as well as strategic services. She is part of OPRG's (Omnicom PR Group's) global leadership team. ​ Before Porter Novelli, Janaczek was President, BCW New York, spearheading the firm's largest market and managing Fortune 500 clients. She sat on BCW's Global Board and was Chair, Client Risk Committee. ​Earlier in her career, Janaczek was Managing Director of Healthcare at Cohn & Wolfe. Her background includes extensive work with prescription medications and Rx to OTC switches. She has worked closely with leading companies such as AbbVie, GlaxoSmithKline, Gilead, Johnson & Johnson, Merck, Novartis and Novo Nordisk, among many others, providing strategic counsel for U.S. and Global programs. She expanded her role with Novartis Pharma AG by working in-house as Global Brand Manager in Basel, Switzerland. ​

In this informative episode, Dr. Aly-Khan Lalani and Dr. Christopher Wallis are joined by Dr. Frédéric Pouilot, a urologist-oncologist and researcher in molecular imaging at the CHU de Québec-Université Laval Research Center. Together, they unpack the evolving role of PSMA PET in prostate cancer and how advanced imaging tools are reshaping treatment decisions. The conversation also looks ahead, to the future of dynamic imaging, and its potential to revolutionize personalized cancer care.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, J&J, Merck, Pfizer, Eisai and AbbVie.

Good evening: The show begins in Switzerland where a decision is made to build Roche and Novartis plants in the US... 1927 SWITZERLAND This appears to be an email from John Batchelor detailing the schedule for a CBS Eye on the World radio/podcast show. Here's a brief summary of the program segments: First Hour: 9:00-9:15: Markets - Switzerland Pharma and US Manufacturing (Liz Peek) 9:15-9:30: Markets - Biden in Disorder (Liz Peek) 9:30-9:45: Lebanon - Hezbollah Weapons (David Daoud, Bill Roggio) 9:45-10:00: Iran - Discussed as "Defeated in All Directions" (David Daoud, Bill Roggio) Second Hour: 10:00-10:15: Trade and Congress history (Philip Wallach, AEI/Civitas Institute) 10:15-10:30: Continued Trade and Congress discussion 10:30-10:45: Russia and Oil Prices (Ekaterina Zolotova) 10:45-11:00: China and Deepseek Deceptions (Jack Burnham) Third Hour: 11:00-11:15: London Calling - Blaming Japan, Germany, China (Joseph Sternberg) 11:15-11:30: London Calling - Rachel Reeves in Washington 11:30-11:45: Antisemitism at Harvard (Peter Berkowitz) 11:45-12:00: Progressivism at Harvard (Peter Berkowitz) Fourth Hour: 12:00-12:15: Iran Nuclear Weapons (John Bolton) 12:15-12:30: USAF Kinetic Warfare in CENTCOM (General Blaine Holt) 12:30-12:45 & 12:45-1:00: Soviet Kompromat and Trump in the 1980s (Craig Unger) Would you like me to elaborate on any of these segments or topics?

What do William Wallace, smart pill bottles, and pharma sales have in common?They all showed up in this week's #TheShot of #DigitalHealth Therapy. Jim Joyce and I had a chat with Innes Meldrum - Scottish-born, New Jersey-rooted CEO of AdhereTech. Innes unpacks his journey from flunking high school to running $Big brands and now cracking one of healthcare's stickiest problems: medication adherence. We covered:

Le vice-président américain JD Vance achève une visite en Inde où il y a rencontré le Premier ministre Narendra Modi, pendant laquelle les deux ont négocié au sujet des mesures tarifaires envisagées par Donald Trump. À l'ordre du jour notamment, les médicaments, car l'Inde est un géant de l'industrie pharmaceutique. C'est un euphémisme d'affirmer que les États-Unis sont extrêmement dépendants des médicaments produits en Inde : près d'un générique sur deux consommés y est fabriqué. On parle ici de traitements contre l'hypertension, les troubles de la santé mentale ou encore le diabète. Car il faut le rappeler, si l'Inde est le premier fournisseur de médicaments au monde, c'est aussi le premier fournisseur des États-Unis. L'an passé, ce sont près de 13 milliards de dollars de médicaments indiens qui ont été exportés sur le sol américain.Pourtant, avant la pause de Donald Trump et donc les négociations en cours, l'Inde était visée par les droits de douane américains, puisqu'il était question d'une surtaxe de 26%. Cela veut donc dire que tout produit fabriqué en Inde arrivant aux États-Unis pourrait être taxé à cette hauteur, y compris donc les médicaments.À lire aussiEn visite en Inde, J.D. Vance affiche son optimisme commercial et sa proximité idéologique avec Narendra ModiÉconomiquement avantageux, sanitairement dangereux Mais il ne s'agit pas de marchandises lambda : il est question de santé publique. La conséquence de l'application des mesures tarifaires de Donald Trump, c'est évidemment un risque sur la santé des Américains en raison d'une hausse des prix.Car les coûts de production en Inde sont trois à quatre fois moins élevés qu'aux États-Unis. Cela permet à Washington d'économiser des milliards de dollars en frais de santé. Rien qu'en 2022, d'après le cabinet de conseil IQVIA, les économies réalisées grâce aux génériques indiens se sont élevées à 219 milliards de dollars.Un pas vers Donald TrumpSi l'objectif de Donald Trump, c'est de relocaliser la production aux États-Unis, cela ne se fait pas du jour au lendemain. Les Américains ne disposent pas forcément des principes actifs sur leur sol pour fabriquer les médicaments en tant que tels. D'autant que leur deuxième fournisseur, c'est la Chine, pays le plus touché par les mesures du président américain. Devant telle situation, plusieurs géants européens présents en Inde notamment ont annoncé des investissements massifs aux États-Unis, avec l'ambition d'anticiper les hausses des prix. Le laboratoire Roche prévoit 50 milliards de dollars pour renforcer ses capacités de production et de diagnostic sur le sol américain. Novartis de son côté parle de 23 milliards sur cinq ans. Donc pour le moment, si on ne s'en tient qu'aux annonces, le président américain obtient des résultats. Mais pour toutes les raisons que l'on vient de détailler, Washington et New Delhi n'ont pas d'autres choix que de discuter. Le bras de fer est diplomatique, mais aussi économique. On a pu le voir ces dernières heures avec la visite de JD Vance à New Delhi. Sauf que la particularité, c'est qu'à court terme, pour les Américains, il est impossible de remplacer l'approvisionnement indien. Ces produits sont vitaux, car l'Inde est un véritable pilier de la santé aux États-Unis. C'est en fait l'un des meilleurs exemples de produit à demande inélastique, à savoir des produits dont on ne peut pas se passer. La question maintenant, c'est jusqu'à quel prix ! À lire aussiComment l'Union européenne compte éviter les pénuries de médicaments?  

WEF leitet Untersuchung gegen Klaus Schwab ein, Novartis und Roche wollen Milliarden in den USA investieren, Ukraine – der fragwürdige Friedensplan von Trump, «Paris noir» – Centre Pompidou würdigt schwarze Kunstschaffende

This podcast features malaria experts Caroline Boulton (Global Program Head, Malaria, at Novartis); Sherwin Charles (CEO, Goodbye Malaria); and Carlos Chaccour (Researcher and Visiting Scholar, Navarra Institute for International Development). The conversation delves into the current malaria response, examining shifts in international funding, R&D innovations, drug resistance challenges, emerging prevention tools, and the impact of climate change.The podcast is hosted by IQVIA's Daniel Mora-Brito, Engagement Manager, Global Health, EMEA Thought Leadership.

While much of the country was off celebrating Easter and Passover this weekend, the FDA—and its new leader Marty Makary—were busy making news. Makary, who was confirmed as FDA commissioner last month, gave his first major interview, where he unveiled a new regulatory pathway for rare disease therapies and addressed the “epidemic of distrust” he feels is imperiling the agency. Makary also shared his thoughts on the conflicts of interest he sees between the FDA and pharma industry, highlighting a new directive to ban industry representatives from serving on the agency's advisory committees—a move experts believe will have minimal impact in reducing COIs.Makary also touched on vaccines and what he believes to be the cause of autism. On this, he was more restrained than his boss, HHS Secretary Robert F. Kennedy Jr., who continues to insist on re-investigating what he believes is a link between autism and vaccines. The interview comes as more former FDA officials sound the alarm about the changes happening within the agency.Elsewhere on the policy front, President Donald Trump continues to threaten tariffs on pharma products. In response, two more companies, Roche and Regeneron, are committing billions of dollars to enhance their U.S. footprints. They join Novartis, J&J and Eli Lilly in this regard, with the latter additionally promising to manufacture its investigational oral obesity drug orforglipron in the U.S.That announcement followed the news that orforglipron generated “injectable-like efficacy” in a Phase III diabetes trial. Lilly intends to submit for approval of the pill for weight management by the end of this year and diabetes in 2026. Not to be outdone, chief rival Novo Nordisk revealed Saturday that it has already filed for FDA approval of an oral formulation of its own blockbuster, semaglutide, for overweight and obesity.Finally, make sure to check out this week's edition of BioPharm Executive where we take a deep dive into another sizzling space—transthyretin amyloid cardiomyopathy (ATTR-CM)—and find out which pharma CEO has the biggest golden parachute.

L'episodio di oggi racconta la straordinaria storia di un fisico nucleare e imprenditore di fama internazionale. Parliamo di Stefano Buono, co-founder e CEO di newcleo.Fondata nel 2021 insieme a Luciano Cinotti ed Elisabeth Rizzotti, newcleo sviluppa reattori nucleari di ultima generazione destinati a produrre energia pulita, sicura e sostenibile. In modo del tutto innovativo, i reattori di newcleo utilizzeranno le scorie nucleari come combustibile eliminando la complessità dello smaltimento dei rifiuti derivanti dall'energia nucleare. In un solo anno newcleo ha raccolto 400 milioni di euro con round partecipati anche da Exor, Liftt e Club degli investitori, e nel 2023 ha lanciato un aumento di capitale da 1 miliardo di euro.Ma questa non è la prima esperienza imprenditoriale di Stefano, nel 2002 Stefano fonda con Paolo Pomè l'Advanced Accelerator Applications per commercializzare un brevetto sviluppato durante gli anni al CERN insieme a Carlo Rubbia e sviluppare prodotti di medicina nucleare per la diagnostica PET e SPECT e la terapia oncologica. Nel 2017 viene registrato il Lutathera, un medicinale per la cura dei tumori dell'intestino, dando inizio alla crescita esponenziale del mercato dei prodotti radiofarmaceutici. Advanced Accelerator Applications è stata quotata al Nasdaq e poi venduta a Novartis per 3.9 miliardi di dollari ma la crescita è ancora strabiliante, contando 1100 dipendenti, sedi in 11 paesi e una rete di distribuzione in 30 paesi.La passione per la scienza e lo spirito imprenditoriale sono sempre stati centrali nella vita di Stefano.Ascoltando Stefano capirete infatti che ha l'ambizione di un imprenditore ma l'anima di uno scienziato interessato ad impatto e risultati. E' una persona super privata non interessata a esaltare il suo successo, quindi siamo particolarmente lusingate ci abbia dedicato un po' del suo tempo prezioso. Con Stefano abbiamo parlato della sua vita da innovatore e dell'importanza del nucleare per produrre un'energia più pulita, indipendente e sostenibile. Speriamo che la chiacchierata possa essere utile per approfondire una tematica così attuale, importante e a volte controversa.SPONSORClemi's Market è il brand di healthy food che ho lanciato con mia sorella e ho una bellissima notizia da annunciarvi, da oggi potete trovare due gusti delle nostre barrette energetiche in 95 Esselunga in giro per l'Italia e presto anche su Esselunga.com ! Potete trovare la lista esatta dei negozi qui: https://www.clemismarket.com/pages/store-locatorSe state cercando uno snack sano ma allo stesso gustoso con un etichetta pulitissima di soli 5 ingredienti naturali, provatele e fatemi sapere cosa ne pensate.

“Covid was not a public health event, although it was presented as such to the world's population,” writes ex-pharma executive Sasha Latypova in The Covid Dossier coauthored by Debbie Lerman. “It was a global operation, coordinated through public-private intelligence and military alliances and invoking laws designed for CBRN (chemical, biological, radiological, nuclear) weapons attacks.” Sasha Latypova is a retired pharmaceutical R&D executive with 25 years of experience, having managed contract research organizations for over 60 companies, including Pfizer and Novartis. She specialized in cardiovascular safety assessments, collaborating with the FDA. More at https://x.com/sasha_latypova and https://sashalatypova.substack.com Connie Shields advocates for ostrich farmers and resists government overreach in Canada. More at https://unlockalberta.substack.com Gwen Lynn is an environmental safety scientist and host of In A Green Minute. With a BS and MS in Environmental Science, she manages health and safety for construction and film industries, specializing in sustainability. She hosted Outdoor Wild Kids Adventures. More at https://inagreenminute.com 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at https://drdrew.com/sponsors  • HEART FACTORS PLUS - A powerful formula packed with L-arginine, a key amino acid that's been shown to enhance nitric oxide physiology and could play a key role in supporting healthy blood flow and circulation. Get a FREE bottle with your order at https://heartfactorsplus.com/drew • ACTIVE SKIN REPAIR - Repair skin faster with more of the molecule your body creates naturally! Hypochlorous (HOCl) is produced by white blood cells to support healing – and no sting. Get 20% off at https://drdrew.com/skinrepair • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at https://drdrew.com/fatty15 • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Trump has signaled support for removing the IRA's 'pill penalty', with analysts cautiously optimistic about the executive order. Tariffs are in focus as Q1 earnings get underway, with EU and US pharmas making demands of the European Commission. Former FDA officials warn of potential implications of workforce cuts at the FDA. J&J sets the tariff tone as Q1 earnings begin to roll in. Experts offer advice on optimizing process development and validation steps for cell and gene therapies. In other news, bluebird's second suitor, Ayrmid, fails to make an offer, and the top 6 highest-paid pharma CEOs in 2024 are revealed.The top 6 highest paid pharma CEOs in 2024 have been revealed, with Johnson & Johnson's Joaquin Duato no longer holding the top spot. Duato has urged for a tax fix rather than tariffs to drive US pharma manufacturing. Viking Therapeutics saw a share rally after rival Pfizer discontinued an obesity candidate. Johnson & Johnson's Q1 earnings beat analyst estimates, thanks to Tremfya and Carvykti. Novartis has pledged a $23 billion boost to US operations amid tariff threats. Trump has signaled support for removing IRA's pill penalty and opened a national security probe on pharma imports. The industry is facing uncertainty due to ongoing tariff drama. Trilink's grna for gene editing has been successful, offering high-purity custom guide RNAs for research purposes. Trump's tariff pause sparked a late-day rally for pharma stocks. Some companies, like Glycomine, Merck, and Boehringer Ingelheim, have received significant funding or made deals in the biopharma sector.Senior Editor Annalee Armstrong encourages readers to suggest topics for future coverage in the biopharma industry.

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad, and one ugly. Up this week: The good — Novartis to invest $23B in U.S. manufacturing and R&D, including seven new sites The bad — U.S. urged to invest $15B to counter China's biotech rise The ugly — Trump signals ‘major' tariffs on pharma, urging manufacturing shift back to U.S.

In this edition of The Rob & Jai Show, Paul Smith, President & COO of Orasis Pharmaceuticals, joins Dr. Rob Rothman and Dr. Jai Parekh for a compelling conversation on his career path and the commercialization of Qlosi™—a novel, FDA-approved, low-dose pilocarpine eye drop for the treatment of presbyopia.With more than two decades of experience across Alcon, Novartis, and now Orasis, Smith reflects on his unique career trajectory from tech startups to ophthalmic leadership, the importance of cross-functional experience, and how a shared vision with founder & CEO Elad Kedar led him to the helm of a company now reshaping the presbyopia landscape.In this episode, you'll learn:Why Qlosi™ was formulated at the lowest approved concentration of pilocarpine to prioritize safety, tolerability, and functional vision.How Orasis is differentiating its launch by learning from past category efforts and focusing on real-world expectations and patient needs.The company's go-to-market strategy, including a hybrid access model and the role of optometry in driving adoption.Why Paul believes innovation in eye care thrives on collaboration, humility, and continuous learning.What makes presbyopia such a powerful entry point into the broader continuum of vision care.With a clear mission, strong leadership, and a product designed with patients in mind, Orasis is setting a new standard in treating one of the most common unmet needs in eye care.Don't miss this thoughtful and inspiring discussion—subscribe to the OIS Podcast today to stay ahead of what's next in ophthalmic innovation!

Where do you draw the line as a leader?Stan Howell, a pharmaceutical powerhouse with 25+ years at giants like Johnson & Johnson, Merck, and Novartis, shares a powerful message.He's now risen to the corner office as COO at Wedgewood holding true to his personal values and guiding principles.Wedgewood is the largest US veterinary compounding pharmacy, serving over 70,000 vets and one million animals yearly. He didn't have some grand plan; he chose to seize the opportunities and learned along the way. Stan's journey from a packaging line to leading global operations is packed with unexpected turns and powerful lessons in leadership, discipline, and the criticality of passion. Learn how he navigated massive industry shifts and why he believes authentic communication is the only communication that truly resonates. You'll also Discover-A Surprising Key to Accelerating Your Career -Why Motivation is Overrated in Leadership -An Unexpected Downside of Becoming Indispensable -How to Craft a Communication Strategy That Works -A Simple 3-Word Blueprint for True Leadership -----What are your non-negotiable principles in your career?-----Follow Stan on LinkedIn here: https://www.linkedin.com/in/stan-howell/Learn more about Wedgewood: https://www.wedgewood.com/-----Connect with the Host, #1 bestselling author Ben FanningSpeaking and Training inquiresSubscribe to my Youtube channelLinkedInInstagramTwitter

Ever wonder how culture and language barriers affect diagnosing chronic spontaneous urticaria (CSU) in Latinx patients? In this episode, allergist Dr. Juanita Mora joins Kortney and Dr. Gupta to discuss chronic spontaneous urticaria (hives) and the unique challenges faced by the Latinx community. They highlight the importance of cultural competency in health care and the barriers that Latinx patients often encounter, such as language differences and access to specialists. They also discuss how Latinx patients are often not given all treatment options for hives, such as biologics.  Dr. Mora emphasizes the importance of having resources available in Spanish and encourages patients and families to advocate for their care. They explore practical tips on how technology, family support, and proper patient education can help overcome barriers, leading to better diagnosis, treatment, and improved quality of life for Hispanic patients managing CSU. What we cover in our episode about chronic hives in the Latinx community: Diagnosing hives in skin of color: How CSU symptoms can present differently on darker skin tones, making accurate diagnosis harder.  Overcoming barriers for Latinx patients: The specific hurdles the Latinx community faces like language barriers, limited access to Spanish-speaking allergists, and challenges obtaining advanced treatments such as biologics. Role of family and community support: How involving family members and community leaders can improve CSU awareness, reduce stigma, and encourage patients to seek timely medical treatment. Importance of Spanish-language patient education: Why accessible, culturally relevant education and resources in Spanish are essential for empowering Latinx patients to manage their CSU effectively. Cultural beliefs and CSU diagnosis: How cultural perceptions around health and family influence the timing of diagnosis and willingness to seek medical care. Resources Spanish ¿Qué es la urticaria crónica? Urticaria Crónica - Dr. Antonio Olvera  Urticaria crónica espontánea/idiopática (erupción crónica) Protocolo urticaria cronica  Resources English Chronic Urticaria Management, Resources & Glossary of Terms Chronic Hives: 10 Actions to Support Your Mental Health Why Are My Hives Not Going Away? Made in partnership with The Allergy & Asthma Network. Thanks to Novartis for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

This content is for informational and entertainment purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.----------------------------------------Welcome to Episode 87 of the Investing in Impact podcast. Today, I'm joined by Dr. Andy Kuper, Founder and CEO of LeapFrog Investments, a pioneering firm that has reshaped how global capital can drive profit with purpose.Dr. Andy Kuper, founder and CEO of LeapFrog Investments, has redefined how private capital can create meaningful change. Since launching the firm in 2007, Kuper has led with a bold vision: to deliver "Profit with Purpose" by investing in businesses that generate strong returns while solving real-world challenges across Asia and Africa.

Discover how to revolutionize your organization by embedding inclusion into its very DNA. Explore the foundations of Amri's groundbreaking book, "Reconstructing Inclusion," which challenges the norms of traditional DEI approaches. Through his experiences at Novartis, Amri shares how organizations can cultivate environments where everyone thrives by aligning skills and capabilities with their purpose.Addressing the elephant in the room, we tackle the current backlash against DEI efforts and explore the concept of anti-fragility. Learn how creating spaces for civil dialogue and fostering cognitive diversity can combat ideological resistance and enhance productivity. Amri also highlights how focusing on agency and prevention versus (over)reaction leads to a more sustainable and inclusive organizational culture.We close the conversation unpacking the nuances of cultural intelligence and relational fitness, vital tools for navigating the complexities of building inclusive environments for all. Join us for this transformative conversation where you will walk away with actionable strategies to foster growth, collaboration, and inclusivity in your organization.What You'll Learn- How to build sustainable and inclusive organizations.- A challenge to traditional DEI frameworks.- An introduction to the COST model—Care, Openness, Safety, and Trust.- Ways to create vibrant, thriving work environments that inspire and empower everyone.Podcast Timestamps(00:00) - Creating Inclusive and Generative Organizations(10:27) - Navigating DEI Backlash and Anti-Fragility(23:02) - Creating Inclusive Organizations(28:20) - Embracing Inclusion Beyond Surface Identities(41:51) - Navigating Cultural Intelligence for Inclusion(47:46) - Sustainable Inclusion Practices in OrganizationsKEYWORDSPositive Leadership, Inclusive Organizations, Social Capitalism, Inclusion Strategy, DEI Frameworks, Sustainable Practices, Anti-Fragility, Cognitive Diversity, Respectful Dialogue, Cultural Intelligence, Relational Fitness, Inclusive Leadership, Collaborative Growth, Mutual Understanding, CEO Success